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Abstract
Background: Childhood undernutrition remains a significant global health challenge accounting for over half of all
under 5 child mortality. Moderate acute malnutrition (MAM), which leads to wasting [weight-for-length z-scores
(WLZ) between − 2 and − 3], affects 33 million children under 5 globally and more than 2 million in Bangladesh
alone. We have previously reported that acute malnutrition in this population is associated with gut microbiota
immaturity, and in a small, 1-month pre-proof-of-concept (POC) study demonstrated that a microbiota-directed
complementary food formulation (MDCF-2) was able to repair this immaturity, promote weight gain and increase
plasma biomarkers and mediators of healthy growth. Here we describe the design controlled feeding study that
tests whether MDCF-2 exhibits superior efficacy (ponderal growth, host biomarkers of a biological state) than a
conventional Ready-to-use Supplementary Food (RUSF) in children with MAM over intervention period of 3 months.
Methods: Two separate cohorts of 12–18-month-old children will be enrolled: 124 with primary MAM, and 124
with MAM after having been treated for severe acute malnutrition (post-SAM MAM). We have established several
field sites in an urban slum located in the Mirpur district of Dhaka, Bangladesh and at a rural site, Kurigram in the
north of Bangladesh. The two groups of children receiving MDCF-2 and RUSF will be compared at baseline (pre-
intervention), after 1 month, at the end of intervention (3 months), 1 month after cessation of intervention, and
every 6 months thereafter for 4 years.
Discussion: This study will determine whether daily, controlled administration of MDCF-2 for 3 months provides
superior improvements in weight gain, microbiota repair, and elevated levels of key plasma biomarkers/mediators
of healthy growth compared to the control RUSF formulation. The pathogenesis of MAM is poorly defined and
there are currently no WHO-approved treatments; results from the current study of children with primary MAM and
post-SAM MAM will shed light on the effects of the gut microbiota on childhood growth/development and will
provide a knowledge base that may help improve complementary feeding practices.
Trial registration: The primary MAM and post-SAM MAM trials are registered in Clintrials.gov (NCT04015999 and
NCT04015986, registered on July 11, 2019, retrospectively registered).
Keywords: Moderate acute malnutrition (MAM), Severe acute malnutrition (SAM), Microbiota Directed
Complementary Food (MDCF), Ready to use Supplementary Food (RUSF)
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Background
Moderate acute malnutrition (MAM), a major global
health problem, is defined as wasting (weight-for-length
z-scores between <− 2 and − 3 compared to WHO Child
Growth Standards) and/or mid-upper-arm circumfer-
ence (MUAC) greater or equal to 115 mm and less than
125 mm. According to the 2017 Global Nutrition Report,
worldwide 52 million children under 5 years of age (8%)
were acutely malnourished while stunting affected 23%
or 155 million [1]. Bangladesh has one of the highest
burdens of childhood undernutrition in the world. Ac-
cording to the 2014 Bangladesh Demographic Health
Survey (BDHS), among children under 5, 36% were
stunted, 12% had severe stunting (LAZ < -3) [2] and 15%
were wasted (WLZ < -2), with more than 2 million clas-
sified as suffering from MAM, and 450,000 having severe
acute malnutrition (SAM, WLZ < -3) [3]. Malnutrition
costs Bangladesh an estimated 1 billion USD a year [4].
In our previous studies [5, 6], we defined a normal
program of gut microbial community development in
healthy members of a Bangladeshi birth cohort who had
provided fecal samples monthly for the first 60 months
of life. This program of community assembly is de-
scribed by changes in the abundances of a group of 15
bacterial strains that together form a network of covary-
ing organisms (an ‘ecogroup’) and is completed by the
end of the second postnatal year. The same program is
shared by healthy members of birth cohorts residing in
other low- and middle-income countries [6]. Using the
15 ecogroup taxa, we found that Bangladeshi children
with MAM and SAM have impaired gut community de-
velopment; this perturbation is worse in children with
MAM compared to SAM and is not repaired by cur-
rently available nutritional interventions, which are not
designed based on knowledge and/or consideration of
gut microbial community development [6].
Recently, we have designed prototypes for nutritional in-
terventions that are composed of locally available, afford-
able, culturally acceptable complementary foods commonly
consumed in Bangladesh. Preclinical studies using gnoto-
biotic mice and piglets colonized with members of the gut
microbiota from Bangladeshi children with acute malnutri-
tion revealed that these formulations contain nutrients that
increase the representation and expressed beneficial func-
tions of growth-promote gut bacterial strains that are un-
derrepresented in the microbiota of affected children [5].
Several of these microbiota-directed complementary food
(MDCF) formulations were subsequently tested in a pre-
POC study involving 12–18-month-old Bangladeshi chil-
dren with MAM living in an urban slum (Mirpur) located
in a district of the nation’s capital city [5]. This 1-month
long, four-arm, controlled feeding study tested three
MDCFs and a commonly used, rice-lentil-based, ready-to-
use supplementary food (RUSF) that was not designed with
the intention of changing gut microbial community struc-
ture or function. One of the MDCFs, MDCF-2, was distin-
guished from the other formulations based on its superior
ability to (i) repair the microbiota of children with MAM to
a configuration that resembled that of healthy individuals
living in the same community, and (ii) change the levels of
multiple plasma proteins involved in mediating various as-
pects of metabolism, bone growth, immune function and
neurodevelopment towards a healthy state [5, 6]. These re-
sults support the notion that repair of impaired gut micro-
bial community development could represent a new
therapeutic concept for restoring healthy growth.
The pre-POC study involved small numbers of children
(15–17/arm) and the 1-month long intervention was too
brief to determine whether a substantial and durable re-
pair of the microbiota, and the changes in the plasma
proteome, would be accompanied by substantial and sus-
tained changes in ponderal and linear growth. Here, we
describe our protocols for POC trials designed to assess
whether compared to RUSF, administration of MDCF-2
to larger numbers of children with MAM for longer pe-
riods of time will produce durable changes in the configu-
rations of their gut communities, their plasma proteomes,
anthropometric indicators of their growth, and their mor-
bidities. Two cohorts of 12–18-month-old Bangladeshi
children will be enrolled; one with primary MAM and the
other with MAM after having been treated for severe
acute malnutrition (post-SAM MAM). In each cohort,
children will be randomized to one of two treatment arms;
members of one arm will receive MDCF-2 while members
of the control arm will receive a standard RUSF. Primary
clinical outcome measures will be the rate of weight gain
and the change in WLZ over the intervention period.
Biospecimens (blood, feces and urine) collected before,
during and after the intervention will be analysed to deter-
mine the extent of gut microbiota repair and the degree of
improvement in levels of plasma biomarkers and media-
tors of healthy growth.
Aim and objectives
To determine whether daily, controlled administration
of MDCF-2 for 3 months provides superior improve-
ments in weight gain, microbiota repair, and elevated
levels of key plasma biomarkers/mediators of healthy
growth compared to the control RUSF formulation. The
sustainability of microbiota repair, growth outcomes and
physiologic state will be assessed over a period of 4 years
through collection and analysis of fecal and blood sam-
ples every 6 months.
Methods
Study design
Fig. 1 describes the designs of the two open-label, ran-
domized control trials.
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Fig. 1 Design of controlled feeding study, including time points where anthropometric data will be collected and biospecimens obtained. a Trial
of children presenting with primary MAM. b Trial of children who present with SAM
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Enrollment began on November, 2018 and it is ex-
pected to continue until July, 2020. Eligible participants
are 12–18-month-old children of either sex with MAM
(WLZ < -2 to − 3; Study 1) or SAM (WLZ < -3; Study 2).
Children will be screened and enrolled through house-
hold surveys by Field Research Assistants (FRAs) follow-
ing pre-specified inclusion criteria (see Table 1 for
inclusion/exclusion criteria). For those who meet the en-
rollment criteria, a full description of the purpose of the
study will be provided, including the number and type of
biological samples to be collected. Parents/legal guard-
ians who are willing to participate will provide a signed
informed consent statement that is witnessed and also
signed by the investigator.
Participants’ guardian/ caregiver who will provide writ-
ten informed consent and participants who satisfy the
inclusion/exclusion criteria will be randomized to one of
the two treatment arms (MDCF-2, RUSF) using the per-
muted block randomization method with concealment
to ensure that the allocation is not made before obtain-
ing consent from parents/caregivers to participate in the
study. A random allocation sequence will be generated
using a computerized random allocation system for per-
muted block randomization to ensure comparable allo-
cation number at a certain equally spaced points in the
sequence of participant assignment. Parallel type of
randomization will be used. Blocks of 2 and 4 will be
constructed to reduce the predictability. Random assign-
ment will be prepared in advance by an independent re-
searcher from icddr b who has no involvement in the
trial. Study staffs are blinded to random assignments.
Sample size calculation
Primary outcome measures will include rate of weight
gain, change in weight and length; change in WLZ,
change in MUAC, change in LAZ, morbidity, extent of
repair of gut microbial community immaturity, and
changes in the levels of key plasma biomarkers of host
physiological state. We plan to include 124 participants
(n = 62/treatment arm) for the primary MAM trial and
for the post-SAM MAM trial. Recruitment of 124 partic-
ipants will give 80% power at 5% significance level based
on the change in WLZ scores of children from the re-
cently completed pre-POC trial of different MDCFs. In
the pre-POC trial of different MDCFs, the baseline WLZ
score of children who received MDCF 2 was − 2.2 and
after 1 month of supplementation was − 1.7. If we con-
sider the WLZ − 2 at baseline and − 1.7 at end line,
pooled standard deviation as 0.53, then the sample size
would be 49 in each arm at 80% power and 5% level of
significance. With 20% attrition, 62 enrolled children will
be needed for each arm in each of the two trials.
Interventions
We have established several field sites in an urban slum
(Mirpur district of Dhaka). The Kurigram field site has
been established in collaboration with the Terre des
Hommes NGO. The post-SAM MAM study will enroll
participants living in both Mirpur and Kurigram while
the MAM study will be conducted in Mirpur. We have
established a Food Processing Laboratory at the Mirpur
and Kurigram field sites in order to freshly prepare the
MDCF-2 and RUSF formulations each day prior to their
distribution on that day to study participants.
Every child will be offered 25 g of the diet twice daily
at the feeding center for the first 4 weeks. In the follow-
ing month, the child will be offered 25 g of the diet at
the feeding center and additional 25 g will be provided
in a clean container to feed at home. In the third month,
two separate containers containing 25 g diet will be pro-
vided every day to each enrolled child at participant’s
home. Feeding information will be collected from
mothers and amount consumed is determined from the
weight of supplement remaining at the end of each feed-
ing session.
Table 1 inclusion/ exclusion criteria of the study participants
Inclusion
Parent(s) willing to sign consent form; the informed consent
document will explicitly request permission to use the collected fecal
samples for future studies, including but not limited to culturing
component bacterial strains
Child age 12–18months and no longer exclusively breast fed
WLZ (<−2 to −3) without bilateral pedal edema at the time of
randomization
Parent(s) willing to bring the child to the feeding center twice daily
for the first 4 weeks of nutritional therapy, once daily for the second
4 weeks, and provide feeding once daily at home for the second 4
weeks, and twice daily at home for the final 4 weeks
Exclusion
Medical conditions: Children with tuberculosis (diagnosis based on
WHO 2014 guidelines which have been incorporated in the national
TB control guidelines of Bangladesh). The guidelines depend upon
the following five diagnostic principles (three out of five should be
positive):
-Specific symptoms of TB
-Specific signs of TB
-Chest X-ray
-Mantoux test
-History of contact
Any congenital/acquired disorder affecting growth, i.e., known case of
trisomy-21 or cerebral palsy; children on an exclusion diet for the
treatment of persistent diarrhoea; having known history of soy, pea-
nut or milk protein allergy
Severe anemia (< 8 mg/dl)
Antibiotic use within the last 15 days for Primary MAM participants
Receiving concurrent treatment for another condition
Failure to obtain informed written consent from parents/guardians
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In the stabilization phase of the post-SAM MAM trial,
each child will be managed according to WHO/icddr,b
guidelines [7]. This protocol includes programmed feed-
ing, micronutrient supplementation, judicious rehydra-
tion, broad spectrum antibiotic treatment and prompt
recognition and management of complications. Upon re-
covery from the stabilization phase, the child will receive
a standard of care dietary protocol based upon the local
diets Halwa and Khichuri. Upon graduation from SAM
to MAM (edema-free WLZ < -2), children will be ran-
domly assigned to one of the two arms.
The schedule for collection of anthropometric data
and biological samples are noted in Fig. 1a, b. Children
will be seen 1 month after cessation of treat for anthro-
pometry and collection of fecal, blood and urine speci-
mens and subsequently every 6 months for up to 4 years.
Production of MDCF-2 and RUSF, and quality control
measures
RUSF is composed of rice, lentil, sugar, soybean oil, and
skimmed milk powder mixed with vitamin mineral pre-
mix. MDCF-2 is composed of chickpea flour, peanut
flour, soy flour, green banana, sugar, soybean oil and
vitamin-mineral premix (Table 2). Both study diets will
be prepared in the icddr,b Food Processing Laboratory
or nutrition centre established at each site. MDCF-2 is
similar in energy density and micronutrient content to
ready-to-use supplementary foods used for treatment of
MAM in Bangladesh and other countries; it meets all
safety and other WHO requirements for a complemen-
tary/supplementary food for 12–18-month-old children
with MAM. Organoleptic acceptability was confirmed
previously in the pre-POC study. Table 2 provides
details about the composition, nutritional content of
MDCF-2 and RUSF.
We will purchase all raw ingredients for the diets from
a single local market in Dhaka; these ingredients will be
used to formulate the diets at both field sites. The icddr,
b Food Safety Laboratory will routinely culture random
samples of the prepared diets on (Luria-Bertani, Manni-
tol Egg Yolk Polymyxin, Tryptic Soy Broth Agar) media
to quantify viable bacteria (including tests for Escheri-
chia coli, Bacillus cereus, Staphylococci), yeast and other
fungi. Nutritional composition will be confirmed at the
Institute of Nutrition, Mahidol University, Thailand
using standard procedures.
Anthropometry, data collection tools and quality control
measures
Body weight will be measured to the nearest 1 g using
the Dual-Purpose Baby Scale (Seca, West Midlands,
UK). Mid upper arm circumference (MUAC) will be
quantified with a MUAC tape. Standing height will be
determined to the nearest 0.1 cm using a Stadiometer,
and supine length will be defined to the nearest 0.1 cm
using an Infantometer (Seca). All scales will be calibrated
daily. At each assessment, 3 consecutive measurements
will be taken and the average value will be recorded.
Interrater consistency (kappa) will be determined at
regular intervals [8].
Collection, preparation and archiving of biological
samples
Biospecimens will be collected before, during and after
the intervention at the time points indicated in Fig. 1a,
b. Venous blood will be collected in EDTA containing
tubes from children and their mothers (2 mL and 5mL,
Table 2 Composition of the study interventions
MDCF 2 (g/100 g) RUSF (g/100 g)
Components Chickpea flour (10) Rice (18.9)
Peanut flour (10) Lentil (21.5)
Soybean flour (8) Skimmed milk powder (10.5)
Green banana (19) –
Sugar (29.8) Sugar (17)
Soybean oil (20) Soybean oil (29)
Micronutrient mix (3.14) Micronutrient mix (3.14)
Protein 11.6 10.2
Fat 20.8 29.5
Carbohydrate 46.2 48.8
Fiber 4.5 4.7
Protein-Energy ratio 11.4 8.2
Fat-Energy ratio 46.0 53.6
Total Calories (per 100 g) 406.8 494.6
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respectively). Plasma will be recovered after centrifuga-
tion, aliquoted into cryovials and the vials will be stored
at -80 °C. After cleaning the genital area with alcohol
pads, 2 mL of urine will be collected into a collection
bag from children and 5mL from their mothers. Follow-
ing centrifugation, aliquots will be maintained at -80 °C
in cryovials. Fecal samples will be collected in a sterile
container, transferred by the field worker within 20 min
of defecation into sterile 2 mL cryovials and immediately
placed in Taylor Wharton CX300 dry cryoshippers that
are pre-charged with liquid N2. Upon return to the la-
boratory, these vials will be stored at -80o C.
Data management and storage
Procedures for data management at icddr,b have been
previously described [9]. An Excel-based program will be
used for scheduling data and sample collection from
each participant. Feeding information, including the total
amount of MDCF-2 and RUSF consumed at each treat-
ment session, and responses to a food frequency ques-
tionnaire, will be collected by the field research
supervisors. Barcoded labels are used for all laboratory
specimens. Unique codes are provided for each of study
sites. All reports, study data collection and administra-
tive forms are coded to maintain study participant confi-
dentiality and for future reference. All study-related
documents are kept in locked cabinets in locked rooms
with restricted access.
Data analysis plan
The two groups of children receiving MDCF-2 and
RUSF in each trial will be compared at baseline and at
different time points as shown Fig. 1a, b. The clinical
outcome variables will include rate of weight gain, an-
thropometric indices, and morbidity. We will perform t-
test, Mann-Whitney test, Chi-Square test and Fisher’s
exact test to compare the primary clinical outcome vari-
ables between the intervention arms. Multivariable linear
regression will be employed to assess the role of the nu-
tritional interventions to the anthropometric outcome.
The data analyst will be blinded to the intervention
arms.
Serially collected biospecimens will be analysed for (ii)
changes in the plasma proteome (characterized by quan-
titative aptamer-based measurements of 5000 different
proteins including those that are biomarkers and media-
tors of bone growth, metabolism, immune function, neu-
rodevelopment and other aspects of physiologic status),
fecal, plasma and urinary metabolomes (utilizing tar-
geted and non-targeted mass spectrometry, including
the products of metabolism carbohydrate components of
the diet and of host metabolic health), (iii) repair of the
gut microbiota (V4-16S rDNA amplicon sequencing to
identify the abundances of ecogroup bacterial taxa and
qPCR assays of the levels/diversity of common entero-
pathogens in fecal samples) and microbiome (shotgun
sequencing of fecal DNA samples to characterize
changes in the representation of microbial genes includ-
ing those involved in the metabolism of various nutri-
ents). A variety of computational tools, including those
that allow for feature reduction [6, 10], will be applied to
these multi-omic datasets to identify significant correla-
tions between components of the microbiota/micro-
biome, proteome, metabolome and clinical parameters.
Discussion
This study is a controlled feeding study with daily moni-
toring of consumption of the nutritional supplements
and comprehensive assessments of feeding histories and
morbidities. The pathogenesis of MAM is poorly defined
and there are currently no WHO-approved treatments;
results from the current study of children with primary
MAM and post-SAM MAM will shed light on the effects
of the gut microbiota on childhood growth/development
and will provide a knowledge base that may help im-
prove complementary feeding practices. The ability to
comprehensively characterize the biological state of chil-
dren with MAM by quantitative measurements of 5000
plasma proteins may define different subsets of children
within the coarser classification of MAM, and will help
determine the relationship between treatment effects on
the levels of various mediators of growth and observed
growth outcomes. The 3-month period of intervention
and subsequent 4-year follow up permits assessment of
the durability of effects within and across treatment
arms and their relationship to starting physiologic and
microbial community states. A weakness of the study is
that it is not possible to attain full blinding since the test
formulations are not packaged.
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